** Shares of Orthocell fall as much as 10.1% to A$0.620, posting their biggest intraday pct loss since March 16, 2023
** Biotech firm says it will raise A$17 mln ($11.28 mln) via placement of 28.3 mln shares
** Issue price of A$0.60 per share is at a 13% discount to stock's last close
** Co says funds will be used to launch its nerve repair medical device Remplir in the United States
** Stock hits lowest level since Oct. 14
** About 1.2 mln shares change hands, 1.5x the 30-day avg
** Stock up 62.3% YTD, as of 0308 GMT
($1 = 1.5076 Australian dollars)
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。